- Status:
- Topic selection
- Technology type:
- Medicine
- Decision:
- Not selected
- Reason for decision:
- Not eligible for Health Technology Evaluation guidance
- Further information:
- The 2024 voluntary scheme for branded medicines, pricing, access and growth states that NICE will continue to evaluate all new active substances and significant indications, except where there is a clear rationale not to do so. Decision makers have concluded that the clear rationale to not evaluate your product is due to Nivolumab-relatlimab being a new form of administration of existing guidance TA950. Therefore, proceeding to a NICE evaluation is not likely to add any further value to the system. Please see eligibility criteria within the prioritisation manual for further information.
- ID number:
- 12178
Email enquiries
If you have any queries please email [email protected]
For further information on how we select topics for development, please see our page about prioritising our guidance topics